Tocilizumab versus adalimumab for rheumatoid arthritis - Authors' reply

Affiliations

¹ University Hospitals of Geneva, Geneva, Switzerland. Electronic address: cem.gabay@hcuge.ch.
² University of California, San Diego, La Jolla, CA, USA.

Comment

Cem Gabay et al. Lancet. 2013.

. 2013 Aug 3;382(9890):395.

doi: 10.1016/S0140-6736(13)61670-0.

¹ University Hospitals of Geneva, Geneva, Switzerland. Electronic address: cem.gabay@hcuge.ch.
² University of California, San Diego, La Jolla, CA, USA.

No abstract available

Comment on

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.
Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A; ADACTA Study Investigators. Gabay C, et al. Lancet. 2013 May 4;381(9877):1541-50. doi: 10.1016/S0140-6736(13)60250-0. Epub 2013 Mar 18. Lancet. 2013. PMID: 23515142 Clinical Trial.
Tocilizumab versus adalimumab for rheumatoid arthritis.
Felson DT. Felson DT. Lancet. 2013 Aug 3;382(9890):394-395. doi: 10.1016/S0140-6736(13)61669-4. Lancet. 2013. PMID: 23911375 No abstract available.